Durata Therapeutics, Inc. Announces Completion of QT Study of Dalbavancin

SAN FRANCISCO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced results from its QT study of the company’s lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The QT study data, presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), showed that in this study dalbavancin had no clinically significant impact on cardiac conduction.
MORE ON THIS TOPIC